Morgan Ebert, Managing Editor

Cassidy Foley Davelaar, DO, FAAP, CAQSM, shares some of the findings from her research on how social media affects young athletes and their body image at the 2023 American Academy of Pediatrics National Conference & Exhibition.

A recent study presented at the 2023 American Academy of Pediatrics National Conference & Exhibition evaluated how clinicians can ask patients' sexual orientation and gender identity for EHR documentation.

In recent research highlighted at the 2023 American Academy of Pediatrics National Conference & Exhibition, investigators sought to evaluate the level of access and marketing of Delta-8 THC (D8) to minors online.

Varsha M. Puri, DO, shares her latest research on how childhood sexual abuse and incest affect experiences and behaviors in adulthood, which was presented in a poster session at the 2023 American Academy of Pediatrics National Conference & Exhibition.

Leah K. Middleberg, MD, FAAP, explains her research on magnet ingestion and socioeconomic disparities, which was recently presented at the 2023 American Academy of Pediatrics National Conference & Exhibition.

In this Q&A, Kristine H. Schmitz, MD, explains her team's recent research on paternal depression and adverse childhood experiences during the 2023 American Academy of Pediatrics National Conference & Exhibition.

A recent study was highlighted at the 2023 American Academy of Pediatrics National Conference & Exhibition that shed light on the long-term impact of very preterm birth on the health-related quality of life (HRQOL) of infants and identified key determinants.

Nipocalimab (Janssen) may be promising for the antenatal and postnatal management of fetal anemia in pregnancies at high risk for EOS-HDFN , according to data from the phase 2 UNITY study presented at the 2023 American Academy of Pediatrics National Conference & Exhibition

Authors of a study highlighted at the 2023 American Academy of Pediatrics National Conference & Exhibition suggest psychosocial factors are significant contributors to parents' decisions regarding safe sleep

Authors of a study highlighted at the 2023 American Academy of Pediatrics National Conference & Exhibition suggest nature exposure therapy could be beneficial for pediatric with chronic pain

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

This decision marks the first functional constipation treatment approved by the FDA for this patient population.

The REFLECT Scoliosis Correction System from Globus Medical is intended to correct progressive scoliosis in pediatric patients while simultaneously maintaining stability and motion as well as allowing for future modulated growth.

Jonathan Miller, MD, pediatrician and chief of primary care, pediatrics, at Nemours Children's Health in the Delaware Valley, spoke about the latest data regarding early HPV vaccination in children as young as 9 at the 2023 Pediatric Academic Societies meeting.

At the 2023 Pediatric Academic Societies Meeting, presenters provided the benefits of breastfeeding, along with some useful tips for lactation and how to best help your breastfeeding patients.

Contemporary Pediatrics® Editorial Advisory Board Member Steven Selbst, MD, gives a glimpse into some research he was involved in regarding physician burnout at the 2023 Pediatric Academic Societies meeting.

Contemporary Pediatrics® Editorial Advisory Board Member Steven Selbst, MD, discusses what sessions he is looking forward to the most from this year's Pediatric Academic Societies conference in Washington, DC.

Roflumilast is a once-daily, topical phosphodiesterase type 4 (PDE4) inhibitor under development for treatment of inflammatory dermatoses, focusing on the hair-bearing areas including the face, scalp, and trunk.

Following voluntary market withdrawal from Covis Pharma, the FDA has decided to withdraw the approval of Makena and its generics for reducing the risk of preterm birth.

Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor indicated for patients as young at 5 years to control high levels of low-density lipoprotein cholesterol (LDL-C) as a result of HoFH.

A New Drug Application has been submitted to the FDA for potential approval of roflumilast foam 0.3% for the treatment of seborrheic dermatitis in adults and adolescents.

Aflibercept is now approved to treat 5 retinal conditions caused by ocular angiogenesis.

If approved, according to AbbVie, linaclotide would be the first prescription therapy for FC in this patient population.

Recently announced data from the INTEGUMENT-1 phase 3 clinical trial demonstrated positive safety and efficacy results for atopic dermatitis patients 6 years and older treated with roflumilast cream (Arcutis Biotherapeutics).

Learn about the most recent news discussed at the 2022 AAP National Conference and Exhibition.

An advisory panel for the US Food and Drug Administration voted 14-1 to withdraw 17α-hydroxyprogesterone caproate (Makena; Covis Pharma) from the market.

Gregg Sylvester, MD, MPH, chief health officer at CSL Seqirus, discusses an FDA-approved cell-based flu vaccine for children as young as 6 months, trends in childhood vaccination rates, and how to prepare for the upcoming flu season.

Olipudase alfa-rpcp (Xenpozyme; Sanofi) is the first disease-specific, and now, only approved therapy for the treatment of acid sphingomyelinase deficiencies in pediatric and adult patients.

Marina Sirota, PhD, associate professor of pediatrics at the University of California, San Francisco, spoke about the new March of Dimes Prematurity Research Center at UCSF and the impact they hope their research will have on the future of preterm birth.

Craig Shapiro, MD, pediatric infectious disease specialist at Nemours Children's Hospital, sits down to discuss the recent uptick in pediatric monkeypox cases and explains what to do if you suspect your patient to have monkeypox.